Moreover, currently, one of the only treatments for NASH and advanced liver fibrosis in humans is pioglitazone, a PPAR-γ agonist, which thus demonstrates the promising potential of treatments that target these receptors in managing NAFLD and NASH [8]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.